Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels
Status:
Withdrawn
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
Patients with Alpha-1 Antitrypsin Deficiency (AATD) will be enrolled to receive multiple
doses of ARC-AAT Injection. All subjects will require a pre-dose biopsy and a biopsy post
last dose.